Dear Mayo Clinic: Adults up to age 45 and at risk for HPV infection can get vaccine
By Liza Torborg
DEAR MAYO CLINIC: Why is the HPV vaccine now offered to adults and adolescents? I was surprised to hear that it's recommended up to age 45. Will the vaccine do any good for adults who already have HPV?
ANSWER: The Centers for Disease Control and Prevention (CDC) recommends that some adults ages 27 to 45 talk with their health care provider about the human papillomavirus, or HPV, vaccine. The vaccine isn't necessary for everyone in that age group. The focus is on people who weren't vaccinated when they were younger and are at risk for infection. If you're older than 26 and aren't sure if you need the vaccine, ask your health care provider. Although the HPV vaccine can prevent a new HPV infection, it cannot treat one you already have.
HPV is the most common sexually transmitted infection in the U.S. Almost all sexually active people get an HPV infection at some point. In many cases, HPV may not cause symptoms or lead to health concerns, and the body clears the infection without any problems. But certain strains of HPV are dangerous viruses that can lead to cancer and genital warts.
Two strains of HPV cause 70% of all cervical cancer and cervical precancerous lesions. Once cervical cancer develops, it is difficult to treat and can be life-threatening. HPV infections also can lead to other genital and anal cancers in females, as well as penile cancer and anal cancer in males. In addition, HPV causes most oral and throat cancers, as well as genital warts in men and women.
The HPV vaccine has proven to be a safe and effective way to prevent HPV infection. But it can't cure an existing infection. So the best time to get the vaccine is before you are exposed to the virus. That means it's ideal to be fully vaccinated before becoming sexually active.
The vaccine is most effective and has been most extensively studied in children between the ages of 9 and 14. During that time, the immune system response to the vaccine is robust, providing excellent protection against HPV. People in this age group require only two doses of the vaccine, with the second dose given six months to one year after the first. For people who receive their first shot of the vaccine after age 14, a three-dose series is recommended to achieve the most effective immune response.
Until recently, the vaccine wasn't recommended for people older than 26. That's because it provides less benefit after a person has been exposed to the virus, and most people older than 26 already have been exposed. However, the CDC now recommends that people between the ages of 27 and 45 talk to their health care provider about the benefit the vaccine may have for them.
In particular, it may be worthwhile to get the HPV vaccine if you are in that age group and are sexually active outside of a long-term monogamous relationship. At any age, having a new sexual partner significantly increases your risk of a new HPV infection. And due to the seriousness of the diseases HPV can cause, it is important to ensure that you are adequately vaccinated against the virus any time you change partners.
In general, if you are 27 to 45 and are in a long-term relationship with only one sex partner, or if you are not sexually active, you do not need the HPV vaccine. The HPV vaccine offers protection against the medical concerns caused by the HPV virus, some of which can be deadly. If you're older than 26 and you think you may need the HPV vaccine, talk with your health care provider. It is worth considering, because the HPV vaccine has proven to be a safe and effective anti-cancer vaccine. — Dr. Gregory Poland, Vaccine Research Group, Mayo Clinic, Rochester, Minnesota
A version of this article was originally published on the Mayo Clinic News Network.
Related Posts
Dr. Tanios Bekaii-Saab explains common causes of liver damage, how it can lead to liver cancer and what you can do to prevent it.
Enhancing digital literacy and improving access to the internet and digital devices may make it easier for rural smokers to quit.
Dr. Michael Wallace, a Mayo Clinic interventional endoscopist, discusses pancreatic cancer screening and research advancements.